Literature DB >> 17450027

Safety of endoscopy after myocardial infarction based on cardiovascular risk categories: a retrospective analysis of 135 patients at a tertiary referral medical center.

Bret J Spier1, Adnan Said, Karen Moncher, Patrick R Pfau.   

Abstract

GOALS: To establish the safety of endoscopic procedures performed in patients with recent myocardial infarction (MI) based upon specific cardiac risk categories.
BACKGROUND: There are no specific guidelines that dictate when to perform endoscopy in patients after recent MI, as this population may be at increased risk for cardiopulmonary complications at the time of endoscopy. STUDY: Retrospective analysis of data collected over 48 months on 135 patients who experienced a MI and within the next 30 days had an endoscopic procedure performed. Data on chronology of complications and certain cardiac risk categories were collected and analyzed.
RESULTS: There was early termination of endoscopic procedures for a major cardiopulmonary complication in 2 of 135 patients (1.5%). The complications occurred on hospital day 0 postMI. Performance of endoscopic procedures on the day of the MI was found to be a risk factor for a procedure-related complication (P=0.02). ST segment elevation myocardial infarction was seen in 19 patients (16.0%), severely depressed ejection fraction in 30 patients (22.2%), and troponin-I peak greater than 1.6 ng/mL in 96 patients (71.0%). No statistically significant increased risk of endoscopy was found in these subsets of patients (P=0.99).
CONCLUSIONS: Endoscopic procedures can be safely performed early post-MI without imparting a significant cardiopulmonary risk. Timing of endoscopy increases risk of complications, but evidence of significant recent cardiac damage as demonstrated by ST segment elevation, depressed left ventricular ejection fraction, or troponin-I peak greater than 1.6 ng/mL does not increase risk of cardiopulmonary complication.

Entities:  

Mesh:

Year:  2007        PMID: 17450027     DOI: 10.1097/01.mcg.0000225624.91791.fa

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  6 in total

1.  Safety of esophagogastroduodenoscopy within 30 days of myocardial infarction: a retrospective cohort study from a Canadian tertiary centre.

Authors:  Fahad Al-Ebrahim; Khurram J Khan; Waleed Alhazzani; Ahmed Alnemer; Abdullah Alzahrani; John Marshall; David Armstrong
Journal:  Can J Gastroenterol       Date:  2012-03       Impact factor: 3.522

2.  The Clinical Dilemma of Esophagogastroduodenoscopy for Gastrointestinal Bleeding in Cardiovascular Disease Patients: A Nationwide-Based Retrospective Study.

Authors:  Chao-Feng Chang; Wu-Chien Chien; Chi-Hsiang Chung; Hsuan-Hwai Lin; Tien-Yu Huang; Peng-Jen Chen; Wei-Kuo Chang; Hsin-Hung Huang
Journal:  J Clin Med       Date:  2022-06-29       Impact factor: 4.964

3.  Facility- and Patient-Level Factors Associated with Esophageal Variceal Screening in the USA.

Authors:  Jennifer A Flemming; Varun Saxena; Hui Shen; Norah A Terrault; Catherine Rongey
Journal:  Dig Dis Sci       Date:  2015-09-12       Impact factor: 3.199

4.  Endoscopic retrograde cholangiopancreatography in patients with previous acute coronary syndrome.

Authors:  Han-Ra Koh; Chang-Hwan Park; Min-Woo Chung; Seon-Young Park; Young-Joon Hong; Myung-Ho Jeong; Hyun-Soo Kim; Sung-Kyu Choi; Jong-Sun Rew
Journal:  Gut Liver       Date:  2014-11-15       Impact factor: 4.519

5.  Randomized controlled trial of early endoscopy for upper gastrointestinal bleeding in acute coronary syndrome patients.

Authors:  Chen-Shuan Chung; Chieh-Chang Chen; Kuan-Chih Chen; Yu-Jen Fang; Wen-Feng Hsu; Yen-Nien Chen; Wei-Chuang Tseng; Cheng-Kuan Lin; Tzong-Hsi Lee; Hsiu-Po Wang; Yen-Wen Wu
Journal:  Sci Rep       Date:  2022-04-06       Impact factor: 4.379

Review 6.  Safety of Digestive Endoscopy following Acute Coronary Syndrome: A Systematic Review.

Authors:  Alastair Dorreen; Sarvee Moosavi; Myriam Martel; Alan N Barkun
Journal:  Can J Gastroenterol Hepatol       Date:  2016-03-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.